等待開盤 05-13 09:30:00 美东时间
0.000
0.00%
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
今天 11:46
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.
05-12 21:27
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 10.29 percent increase over losses of $(0.68) per share from the
05-12 04:23
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) (the "Company"), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication
04-16 19:04
The earnings results for Metagenomi Therapeutics (NASDAQ:MGX) for Q4 were made ...
03-06 05:14
New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilitiesPre-IND meeting held in 4Q 2025 following MGX-001 preclinical
01-12 21:33
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.
2025-11-13 01:09
Gainers Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 176.6% to $1.21...
2025-11-13 01:05
Metagenomi shares are trading lower. The company reported Q3 financial results.
2025-11-12 05:37
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.60) by 7.87 percent. This is a 7.84 percent decrease over losses of $(0.51) per share from the same
2025-11-12 05:04